American Vanguard Corporation (NYSE: AVD) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated results; dollar amounts below are in millions except per-share data. The company reports one segment and sells crop and non-crop products and licensing royalties.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $135.1 | $124.9 | Up 8% |
| Gross profit / gross margin | $42.4 / 31% | $38.5 / 31% | Profit up 10%; margin broadly stable |
| Operating income | $6.1 | $3.3 | Up $2.8 |
| Net income | $1.6 | $1.9 | Down 19% |
| Diluted EPS | $0.06 | $0.07 | Down $0.01 |
| Net cash used in operating activities | $42.4 | $41.5 | Cash outflow increased $1.0 |
U.S. sales rose 12% to $85.0 million; international sales increased 2% to $50.1 million. U.S. non-crop sales were up 28%, and U.S. crop sales were up 9%. Higher product availability, granular soil insecticide market-share gains and mosquito-control demand supported sales. Gross margin held near 31% as higher sales and improved factory performance were offset by product mix and costs.
Operating expenses increased 3% to $36.3 million. Higher general and administrative costs, including incentive compensation, foreign-exchange effects, credit-loss reserves, audit and transformation costs, were partly offset by lower research, product development and regulatory expenses. Interest expense, net, rose to $3.7 million from $1.7 million, reflecting higher average borrowings and rates. Income tax expense was $1.5 million versus a $0.4 million benefit a year earlier; the 48.9% quarterly effective rate reflected losses in Brazilian subsidiaries that did not generate tax benefits and a prior-year deferred-tax remeasurement benefit.
Financial position and liquidity
At March 31, 2024, cash was $13.7 million, total assets $781.6 million, and total stockholders’ equity $371.6 million. Inventories were $228.3 million, up from $219.6 million at year-end; net receivables were $194.6 million. Current liabilities were $195.4 million, down from $230.5 million, principally as customer prepayments fell to $28.5 million from $65.6 million.
Revolving-credit borrowings were $187.0 million gross ($185.9 million net of deferred loan fees), compared with $138.9 million gross at year-end. The facility has a $275 million limit and matures August 5, 2026. Remaining borrowing capacity under the covenants was $85.0 million, down from $115.0 million at year-end. The company reported compliance with its amended covenants and stated that cash, expected operating cash flow and facility availability should meet needs for the next 12 months. Substantially all company assets are pledged as collateral.
Operating cash use reflected working-capital needs, including $9.4 million of inventory growth and a $37.0 million decrease in customer prepayments. Investing cash use was $3.6 million, mostly capital expenditures. Financing provided $47.7 million, including net line-of-credit borrowings; cash ended the quarter at $13.7 million. The company paid dividends of $0.03 per share. Share repurchases are prohibited during the credit-agreement covenant modification period.
Outlook, risks and unusual items
- Outlook: The filing gives no quantified full-year sales or earnings guidance. Management described global agriculture conditions as stable but mixed, with a strong U.S. dollar, high grain inventories and continued distributor procurement restraint. It expects seasonal inventory building to support sales through the rest of the year; results for the quarter are not necessarily indicative of full-year results.
- Dacthal regulatory action: On April 9, 2024, after quarter-end, the company voluntarily suspended Dacthal sales while EPA reviews a significantly narrower proposed label. The timing and outcome are uncertain. Dacthal sales had contributed to the quarter’s crop sales improvement. Management said a permanent loss of Dacthal sales would affect domestic reporting-unit fair value but, based on its current assessment, would not cause goodwill impairment.
- DOJ matter: The company reached an agreement in principle with the DOJ in January 2024 concerning an investigation focused on potential RCRA violations. The agreement remains subject to court approval; a plea hearing was expected in late May 2024. A loss contingency was recorded, but the filing does not clearly state its amount. Management did not expect a material adverse effect based on the agreement’s terms.
- Other litigation: A Quebec strawberry grower seeks approximately $5 million over alleged crop damage involving Vapam. The company disputes the claims and has not recorded a reserve because loss probability and amount cannot yet be assessed.
- Credit and market risks: The amended facility temporarily relaxed leverage and fixed-charge covenants, with tighter levels scheduled to resume. Borrowing rates are variable; the quarter-end rate was 8.30%. The company does not hedge foreign-currency exposure. Other stated risks include product demand, weather, regulation, competition, supply constraints and product commercialization.
- Other items: A $0.6 million gain on a publicly traded equity investment increased pre-tax income. Foreign-currency translation produced a $1.6 million comprehensive loss. Transformation costs were $1.2 million.
Investor facts to verify
- Monitor EPA’s review of the proposed Dacthal label, the sales suspension and any related sales or impairment effects.
- Confirm the DOJ agreement’s court approval, final penalties or other terms, and the contingency amount.
- Track working-capital conversion, customer prepayments, inventory and operating cash flow, alongside rising debt and interest costs.
- Review covenant headroom and the scheduled return to tighter leverage and fixed-charge coverage requirements.
- Check progress and costs of the transformation program and whether operating-expense increases persist.
- The signature block gives a May 9, 2023 date, although this is the Q1 2024 filing; verify the correct signature date.